Suppr超能文献

皮质类固醇作为骨髓移植相关弥漫性肺泡出血的辅助治疗。内布拉斯加大学医学中心骨髓移植小组。

Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group.

作者信息

Metcalf J P, Rennard S I, Reed E C, Haire W D, Sisson J H, Walter T, Robbins R A

机构信息

Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-2465.

出版信息

Am J Med. 1994 Apr;96(4):327-34. doi: 10.1016/0002-9343(94)90062-0.

Abstract

BACKGROUND

Diffuse alveolar hemorrhage is a frequent complication of treating malignancies with high-dose chemotherapy and bone marrow transplantation and is associated with very high mortality. This disorder's association with pulmonary inflammation, its coincidence with marrow recovery, and the usefulness of corticosteroids for treating other pulmonary hemorrhage syndromes provided the rationale for this study.

METHODS

We retrospectively studied 65 episodes of diffuse alveolar hemorrhage that has occurred in 63 of 603 consecutively treated patients who had undergone high-dose chemotherapy with bone marrow transplantation. Patients were divided into three groups according to the therapy they had received for diffuse alveolar hemorrhage: supportive therapy alone (n = 12); low-dose corticosteroids (30 mg or less of methylprednisolone or its equivalent; n = 10); and high-dose corticosteroids (more than 30 mg methylprednisolone or its equivalent; n = 43). The primary outcome measures were overall survival and survival to hospital discharge, occurrence of respiratory failure requiring intubation, and development of infections subsequent to the diagnosis of diffuse alveolar hemorrhage.

RESULTS

Overall survival at the end of the follow-up period was significantly higher for the high-dose corticosteroid group compared with the supportive therapy group (P = 0.005); however, treatment with low-dose steroids did not increase survival over supportive therapy alone (P = 0.198). In addition, survival to discharge was significantly increased for the high-dose group compared with the other two groups combined (33% versus 9.1%, P = 0.038). Respiratory failure after the diagnosis of diffuse alveolar hemorrhage developed in only 12 of the 22 unintubated patients in the high-dose group compared with 9 of the 10 initially unintubated patients in the other two groups (P = 0.056). Although the incidence of infections was high (40%) subsequent to diffuse alveolar hemorrhage, neither high-dose nor low-dose corticosteroid treatment significantly increased the risk of infections (P > 0.4, all comparisons).

CONCLUSIONS

In this study, high-dose corticosteroid therapy for diffuse alveolar hemorrhage related to bone marrow transplantation was associated with improved total survival and survival to hospital discharge, and decreased development of respiratory failure in these patients. These results suggest the therapy is beneficial, and further prospective studies are warranted to verify the effectiveness of the treatment.

摘要

背景

弥漫性肺泡出血是高剂量化疗和骨髓移植治疗恶性肿瘤时常见的并发症,且死亡率极高。这种疾病与肺部炎症的关联、与骨髓恢复的同时发生,以及皮质类固醇对治疗其他肺出血综合征的有效性为该研究提供了理论依据。

方法

我们回顾性研究了603例连续接受高剂量化疗及骨髓移植患者中的63例发生的65次弥漫性肺泡出血事件。根据患者接受的弥漫性肺泡出血治疗方法,将患者分为三组:仅支持治疗组(n = 12);低剂量皮质类固醇组(30毫克或更少的甲泼尼龙或其等效物;n = 10);高剂量皮质类固醇组(超过30毫克甲泼尼龙或其等效物;n = 43)。主要观察指标为总生存率、出院生存率、需要插管的呼吸衰竭发生率以及弥漫性肺泡出血诊断后的感染发生率。

结果

随访期末,高剂量皮质类固醇组的总生存率显著高于支持治疗组(P = 0.005);然而,低剂量类固醇治疗与仅支持治疗相比并未提高生存率(P = 0.198)。此外,高剂量组的出院生存率显著高于其他两组之和(33%对9.1%,P = 0.038)。高剂量组22例未插管患者中,弥漫性肺泡出血诊断后仅12例发生呼吸衰竭,而其他两组最初10例未插管患者中有9例发生呼吸衰竭(P = 0.056)。虽然弥漫性肺泡出血后感染发生率较高(40%),但高剂量和低剂量皮质类固醇治疗均未显著增加感染风险(P > 0.4,所有比较)。

结论

在本研究中,高剂量皮质类固醇治疗与骨髓移植相关的弥漫性肺泡出血可提高总生存率和出院生存率,并降低这些患者呼吸衰竭的发生率。这些结果表明该治疗有益,有必要进行进一步的前瞻性研究以验证该治疗的有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验